Recent Updates — HYPR
Hyperfine announced preliminary unaudited financial results for the third quarter ended September 30, 2026, reporting estimated total revenue of approximately $6.0 million, representing a 53% sequential increase from the second quarter. For the nine months ended September 30, 2026, estimated revenue was approximately $13.8 million, up 66% year-over-year. The company also reported preliminary net cash burn of approximately $5.6 million for the quarter, a 29% sequential improvement, and expected cash and cash equivalents of approximately $37.9 million as of September 30, 2026. Management reaffirmed its full-year 2026 revenue outlook of approximately $20 to $22 million. Hyperfine is a health technology company that develops the Swoop system, the first FDA-cleared AI-powered portable MRI for brain imaging.
Hyperfine, Inc. received written notice from Nasdaq on September 17, 2026, that its Class A common stock no longer meets the minimum bid price requirement of $1.00 per share due to closing prices falling below this threshold for 30 consecutive business days. The company has an initial compliance period until March 16, 2027, to restore the stock price to at least $1.00 for ten consecutive trading days. Failure to comply may result in a transfer to the Nasdaq Capital Market or potential delisting, though operations and reporting obligations remain unaffected. Hyperfine, Inc. operates in the medical technology industry, specializing in portable MRI systems.
Hyperfine, Inc. reported second quarter 2026 financial results on August 6, 2026. Revenue increased 44.8% to $3.9 million from $2.7 million in the prior year period, driven by a 50% increase in commercial system sales to 12 units. Gross profit rose to $2.0 million with a gross margin of 50.7%. The company reported a net loss of $9.3 million, or $0.09 per share, compared to a $9.2 million loss in the prior year. Cash and cash equivalents stood at $43.5 million as of June 30, 2026. Management reaffirmed full-year 2026 revenue guidance of approximately $20 to $22 million. The company operates in the health technology industry, developing portable magnetic resonance brain imaging systems.